Navigation Links
John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge

HACKENSACK, N.J. (April 4, 2011) The John Theurer Cancer Center at Hackensack University Medical is the only cancer center in New Jersey where advanced prostate cancer patients can receive a cell collection process and infusion of Provenge (Sipuleucel-T). Now, patients can find the complete capabilities of this breakthrough immunotherapy in one center led by one physician.

"We are now able to provide patients with care that is not only innovative for improved outcomes, but convenient and more personal," said Robert Alter, M.D., Co-Chief, Urologic Oncology at the John Theurer Cancer Center. "Throughout the Provenge delivery process, patients are treated by a single team of our expert staff, allowing for a more intimate, comforting course of treatment."

Provenge is the first autologous cellular immunotherapy available for the treatment of advanced prostate cancer, meaning it is designed to use cells from a patient's own immune system to identify and target prostate cancer. The John Theurer Cancer Center participated in the Provenge clinical trials, and began prescribing and infusing patients when the treatment was approved in June 2010. This February, the John Theurer Cancer Center received approval by Provenge manufacturer, Dendreon, to conduct leukapheresis, a cell collection process vital for the development of the immunotherapy.

"Provenge is another example of the cutting-edge treatments we provide our patients at the John Theurer Cancer Center," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services at the John Theurer Cancer Center. "We strive to deliver patients with the latest treatment options and state-of-the-art technology in order to deliver exceptional care."

Provenge treatment at the John Theurer Cancer Center begins with leukapheresis, a cell collection process administered by a clinical assistant. The patient's cells are sent to a Provenge manufacturing facility, where they are combined with a protein that is found in most prostate cancers linked to an immune stimulating agent. The dose of Provenge is then sent back to the cancer center for infusion. This whole process is performed three times over approximately six weeks for complete treatment.


Contact: Jaymie DeGaetano
John Theurer Cancer Center

Related medicine news :

1. The MMRF and John Theurer Cancer Center to host patient symposium
2. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
3. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
4. Oncology basic research director at John Theurer Cancer Center continues transplantation research
5. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
6. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
7. John Theurer Cancer Center to present innovative research at 2 surgical meetings
8. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
9. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
10. The John Theurer Cancer Center recognizes medical physics team for safety track record
11. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is ... pleasing the palates of attendees is of the utmost importance. Whether you are ... get-together, give these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in Las ... Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers men ... surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use device ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... physicians and athletic programs, launches new Wimbledon Athletics Facebook page to ... young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
Breaking Medicine Technology: